Despite the rapid progress in developing and testing weight loss drugs centered around the weight loss effects of GLP-1 receptor agonists, the progress to date is likely just the opening chapter in our understanding of a class of drugs that may now allow the effective treatment of obesity, a previously intractable problem in both human and veterinary medicine. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.